STEAP (Six-Transmembrane Epithelial Antigen of Prostate) is a family of transmembrane proteins, initially identified in prostate cancer cells but expressed across multiple tissues and cancers. Members include STEAP1–STEAP4, with STEAP5 occasionally referenced.
STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1) is a protein that is primarily expressed in prostate tissue and belongs to the STEAP family. It is a transmembrane protein with six transmembrane domains, involved in the transport and signaling across the cell membrane. STEAP1 is highly expressed in prostate cells, while its expression is relatively low in other tissues. This makes it a potential biomarker for prostate cancer, particularly in the development of immunotherapies and targeted drugs for prostate cancer.
STEAP2 (Six-Transmembrane Epithelial Antigen of the Prostate 2) is a transmembrane protein that belongs to the STEAP family and is primarily expressed in the prostate and several other tissues. Similar to STEAP1, STEAP2 plays a role in transport and signaling across the cell membrane. Due to its specific expression in prostate cancer, STEAP2 is being studied as a potential biomarker and therapeutic target, particularly in the development of immunotherapies and targeted drugs for prostate cancer.
STEAP3 is a transmembrane protein that belongs to the STEAP family and is primarily expressed in the prostate, testes, and several other tissues. It plays an important role in transport and signaling across the cell membrane. Due to its expression in certain cancers, such as prostate cancer and breast cancer, STEAP3 is being studied as a potential biomarker and therapeutic target, particularly in the development of targeted therapies and immunotherapies for these cancers.
STEAP4 is a transmembrane protein that belongs to the STEAP family and is primarily expressed in the prostate, liver, and several other tissues. It also plays an important role in transport and signaling across the cell membrane. The expression of STEAP4 is associated with certain cancers, such as prostate cancer and liver cancer, making it a subject of research as a potential biomarker and therapeutic target, particularly in the development of targeted therapies and immunotherapies for these cancers.
Genomeditech provides resources related to the STEAP1, STEAP2, STEAP3, STEAP4 targets, including overexpression cell lines and antibodies, which can support the in vitro activity validation of STEAP-targeting antibodies. These tools will assist researchers in better evaluating and optimizing the development of STEAP-related drugs, advancing their application in tumor immunotherapy.
![86cc4530a1af52460cd00c72fdb7f0be[1].png](https://en.genomeditech.com/storage/ueditor/image/20250815/1755227035127940/6d31d2d19f401f6a3f866a4f2fe6a996.png "/ueditor/image/20250815/1755227035127940/6d31d2d19f401f6a3f866a4f2fe6a996.png")
